| Gene symbol | CXCL5 | Synonyms | ENA-78, SCYB5 | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4q13.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | C-X-C motif chemokine ligand 5 | ||||
| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3301 |
| Trial ID | NCT05677893 |
| Disease | Severe Acute Respiratory Syndrome Coronavirus 2 |
| Altered gene | S|CXCL5 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | MBS-COV|SNS812 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants |
| Year | 2022 |
| Country | United States |
| Company sponsor | Oneness Biotech Co., Ltd. |
| Other ID(s) | SNS812CLCT01 |
| Cohort1: MBS-COV | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||